Lyme Treatment Guidelines — What They Say, Where They're Contested

Treatment of Lyme disease is one of the most genuinely contested areas in U.S. infectious-disease medicine. The disagreement is old, institutional, and well-documented in the federal record. The 2018 HHS Tick-Borne Disease Working Group report to Congress describes the split plainly:

"The medical opinion on diagnosis and treatment of tick-borne diseases is divided into two schools of thought, each described in a set of guidelines: (1) the Infectious Diseases Society of America (IDSA) and other medical societies, and (2) the International Lyme and Associated Diseases Society (ILADS). The IDSA guidelines promote the diagnosis of Lyme disease through recognition of more specific objective manifestations of disease and confirm the diagnosis by two-tiered serological testing, except in cases of early Lyme disease with the erythema migrans rash, which constitutes a clinical diagnosis. The IDSA guidelines usually recommend 10 to 21 days of antibiotic treatment, except in cases of late arthritis where it may be longer. In contrast, the ILADS guidelines promote the use of clinical judgment with an emphasis on both signs and symptoms of disease when diagnosing and treating tick-borne diseases and do not restrict the long-term use of antibiotics." — HHS, 2018, pp. 65–66. Tick-Borne Disease Workin...

That framing — two schools of thought, two guideline documents — is not only the advocates' view. It is the federal government's own description of the field. This article lays out what each side's guidelines say, where they overlap, and where they diverge, and what the evidence and the federal record look like at the seams.

The IDSA/AAN/ACR 2020 guideline

The Infectious Diseases Society of America, American Academy of Neurology, and American College of Rheumatology issued a joint update in late 2020. As one review puts it, this marked "the first update to guidelines on the diagnosis and treatment of LD by the IDSA since 2006" (TTBD 2021), and "the IDSA guideline recommendations remained largely consistent between 2006 and 2020" (TTBD 2021).

The antibiotic architecture is tight. Lyme disease, the panel writes, "is susceptible to antimicrobials from several classes" (IDSA 2020): "doxycycline, amoxicillin, cefuroxime, ceftriaxone, and azithromycin" (IDSA 2020). For the erythema migrans rash, the recommendation is oral therapy:

"We recommend that patients with erythema migrans be treated with either a 10-day course of doxycycline or a 14-day course of amoxicillin or cefuroxime axetil rather than longer treatment courses *(strong recommendation, moderate quality of evidence).Comment: If azithromycin is used, the indicated duration is 5–10 days, with a 7-day course preferred in the United States, as this duration of therapy was used in the largest clinical trial performed in the United States." — IDSA, 2020. Clinical Practice Guideli...

For arthritis, "oral antibiotic therapy for 28 days" (IDSA 2020). For most other manifestations, "14–28 days of an appropriate antibiotic with duration of treatment based on which clinical manifestation is being treated" (IDSA 2020). For patients with Lyme arthritis who fail one oral and one IV course, the guideline advises a referral to a specialist and adds a hard line: "Antibiotic therapy for longer than 8 weeks is not expected to provide additional benefit to patients with persistent arthritis if that treatment has included 1 course of IV therapy" (IDSA 2020).

The single recommendation around which the entire controversy orbits is the one governing patients whose symptoms persist after a recommended course. The panel recommends against more antibiotics:

"For patients who have persistent or recurring nonspecific symptoms such as fatigue, pain, or cognitive impairment following recommended treatment for Lyme disease, but who lack objective evidence of reinfection or treatment failure, we recommend against additional antibiotic therapy *(strong recommendation, moderate-quality evidence).Comment: Evidence of persistent infection or treatment failure would include objective signs of disease activity, such as arthritis, meningitis, or neuropathy." — IDSA, 2020. Clinical Practice Guideli...

The guideline does not deny that such patients exist. It characterizes their frequency as an open question: "The prevalence of persistent symptoms following standard treatment of Lyme disease is unclear" (IDSA 2020), with "persisting or recurrent fatigue, musculoskeletal pain, neurocognitive and other nonspecific subjective symptoms in 10–20% or more 1 year after treatment" (IDSA 2020). It then adds a controlled-trial observation: "the frequency of this symptom complex is the same in controls as in treated Lyme disease patients" (IDSA 2020), and suggests the finding "may represent anchoring to a recent diagnosis of Lyme disease" (IDSA 2020).

That is the evidentiary pillar on which the against-retreatment recommendation rests.

The ILADS counter-position

The International Lyme and Associated Diseases Society reads the same terrain differently. Summarized in the 2012 Senate hearing record:

"The opposing viewpoint is held by the International Lyme and Associated Diseases Society (ILADS). In ILADS’ view, Lyme disease can be difficult to diagnose and treat, may persist after short-term treatment and require additional treatment, and can severely interfere with the patient’s quality of life." — Senate, 2012, pp. 53–54. Lyme Disease: A Comprehen...

A 2023 patient-survey paper states the guideline contrast in one paragraph: "the Infectious Disease Society of America’s (IDSA) treatment guidelines (updated in 2020) recommend 5–28 days of antibiotics depending on symptoms, followed by an additional 2–4-week course of IV antibiotics under certain circumstances" (MDPI 2023), whereas "the International Lyme and Associated Diseases Society (ILADS) treatment guidelines recommend more individualized protocols based on patient responses" (MDPI 2023). The 2018 HHS working group's sentence-level summary is that the ILADS approach "do not restrict the long-term use of antibiotics" (HHS 2018).

Testimony in the 2012 House hearing characterized the IDSA position in a harsher register. "One view, promoted by the Infectious Disease Society of America, is that the disease is "hard to catch and easy to cure" and denies the existence of chronic Lyme disease or persistent infection with the Lyme bacteria." (House 2012) The same hearing's witnesses argued that "there has been extreme controversy regarding the restrictive nature of the IDSA guidelines" (House 2012), which in their view "do not allow for the possibility of chronic infection and severely limit physician discretion on treating the disease" (House 2012). In another witness's words: "The IDSA standard ignores the more common and severe chronic form of Lyme disease that many of my patients suffer from." (House 2012)

A patient-advocacy summary in the 2012 Senate record cited survey data: "60 percent of those who had tried the IDSA short-term treatment protocols had failed to regain their health and 80 percent of patients would not choose to be treated under the IDSA protocols." (Senate 2012) That same statement characterized the IDSA position this way:

"The IDSA supports the view that Lyme disease is hard to catch, easy to cure and that any persistent manifestations in patients after a short treatment of antibiotics are caused by something other than the Lyme bacteria. In their view, patients suffer from no more than the ‘‘aches and pains of daily living’’." — Senate, 2012, pp. 53–54. Lyme Disease: A Comprehen...

Neither of these cited texts is an ILADS guideline; they are the record of how the disagreement has been presented to Congress.

The NIH retreatment trials — same studies, different readings

Four NIH-funded randomized trials of antibiotic retreatment in patients with persistent symptoms have been run in the U.S. (Klempner, Fallon, Krupp, Berende). They are the evidentiary center of the entire fight. The 2022 MDPI review notes the mechanical facts: "Antibiotic retreatment trials of patients with PLD/CLD have been hampered by the lack of a reliable diagnostic markers to determine both entry criteria and treatment outcomes. All of the four NIH-sponsored clinical retreatment trials were quite small; yet, two found a beneficial treatment effect on severe fatigue." (MDPI 2022)

The 2022 HHS Tick-Borne Disease Working Group access-to-care subcommittee report goes further, criticizing how CDC web materials summarize those trials:

"Despite a high-priority designation, the webpage’s treatment of persistence of infection and PLD/CLD does not accurately represent the available science or the controversies still being debated. Without providing references, the discussion of the NIH-sponsored clinical trials on antibiotic retreatment of PLD/CLD dismisses the beneficial treatment effects identified in the Krupp and Fallon trials and disregards important methodologic issues, which were raised about the Klempner trials. Rather than examining the nuances of the trials’ designs and the divergent findings, the discussion presents two erroneous conclusions: (a) the trials proved that the antibiotic regimens, IV ceftriaxone alone or in combination with oral doxycycline, were ineffective and (b) that the perceived lack of benefit from these two regimens implies that all potential antibiotic retreatment regimens would fail. Considering that these small studies excluded 89-99% of patients who sought to enroll, suggesting that all attempts at antibiotic retreatment would be futile is a disservice to patients and clinicians. In support of its position against antibiotic retreatment in PLD/CLD, the webpage discussion turns to the efficacy findings from a more recent European study, but without acknowledging the full extent of that study’s limitations or important mitigating elements." — HHS, 2022. Access to Care and Educat...

That passage — a federal advisory body writing that the CDC's treatment of the retreatment evidence "does not accurately represent the available science or the controversies still being debated" (HHS 2022) — is unusual, and it is part of why the dispute has remained institutional rather than closing.

Where the evidence is genuinely unsettled

Several questions cut across both camps. The 2020 HHS subcommittee on Lyme pathogenesis states plainly: "It has been established that the causative organism of Lyme disease, B. burgdorferi, can persist in a number of animal models and human case studies following infection and treatment with a “standard” course of antibiotics." (HHS 2020) It continues: "Evidence now exists, from the results of experiments in both murine and nonhuman primate models, that persisting B. burgdorferi can be metabolically active, expressing certain bacterial genes and inducing gene expression changes in the infected host, despite being non-culturable following antibiotic treatment" (HHS 2020). The human translation remains open: "it is still unclear whether human patients with ongoing symptoms associated with Lyme disease continue to have an active infection following completion of seemingly appropriate antibiotic therapy" (HHS 2020).

Even accepting persistence in animal models, repeat antibiotic courses in animals carrying persistent organisms "appear to be ineffective" (HHS 2020). That is a finding both sides have had to reckon with.

The underlying evidence base for treatment recommendations is thinner than the strength of those recommendations suggests. The 2018 HHS report: "Recent evaluations by Cochrane (treatment of neurologic Lyme disease) and NICE (Lyme disease treatment guidelines and evidence review in the United Kingdom) found that there is poor evidence based on comparative antibiotic trials to determine the best treatment regimen in Lyme disease manifestations" (HHS 2018). The 2022 HHS subcommittee put it in GRADE terms: "two of the three organizations reviewing the evidence base generally rated the quality as “low”" (HHS 2022). And: "the majority of GRADE-based evidence assessments regarding treatment benefits determined that the evidence is generally of low quality" (HHS 2022). A 2012 House witness made the same point about the UK: "most treatment recommendations are, in fact, based on opinion, not evidence" (House 2012).

Failure rates matter to both camps. The 2022 MDPI review reports: "61% of subjects treated with 30 days of IV ceftriaxone for Lyme encephalopathy failed to return to their pre-Lyme health status" (MDPI 2022). Even in ideal conditions: "even in an ideally treated cohort of 234 patients who received appropriate oral antibiotics, 44% remained symptomatic alone (at moderate to severe levels) or remained symptomatic with functional impairments" (MDPI 2022). A 2022 Johns Hopkins prospective cohort reached a convergent finding under the opposite framing — that even "participants ideally diagnosed and treated for prior LD reported more symptoms on standardized surveys and were more likely to meet an operationalized definition of PTLD than those without prior LD" (JHU 2022). A mainstream summary in the Nesgos review nonetheless holds that "The majority of patients who present with acute LD, and are diagnosed and treated appropriately, do not experience chronic or prolonged symptoms" (TTBD 2021).

What fraction — "10–20% to 36% of patients will have ongoing symptoms" (MDPI 2023) — that represents, and whether those symptoms reflect ongoing infection, immune dysregulation, tissue damage, or anchoring to a recent diagnosis, is the scientific seam.

Definitions are not settled either

The term "chronic Lyme disease" itself has no single meaning. A 2014 BMC review lays out the definitional problem: "Chronic Lyme disease is a term that describes a constellation of persistent symptoms in patients with or without evidence of previous Borrelia burgdorferi infection." (BMC 2014) The field fractures from there:

"There is no standard definition of CLD; the Infectious Diseases Society of America distinguishes between ‘post-Lyme disease syndrome’ or ‘late Lyme disease’ in which arthralgia and other symptoms persist after documented B. burgdorferi infection, while Feder et al. categorize similar syndromes into post-Lyme disease syndrome, symptoms of unknown cause (with our without antibodies to B. burgdorferi), and defined illnesses unrelated to B. burgdorferi infection." — BMC, 2014. Experiences of patients i...

A Lyme disease registry team testifying in 2012 described the terminological bind from inside clinical practice:

"Despite these examples, those of us working with the Registry find ourselves walking a very fine line, even in the use of terminology. For example, if we use the term, chronic Lyme disease, we become discredited by many physicians. If we use the term, postLyme syndrome, we are discredited by those in the community who have been personally impacted. Based on our patient interactions, we believe that there is a protracted clinical course for Lyme disease for many people. But the controversy surrounding these long-term symptoms has created a polarizing tension between patients and providers." — Senate, 2012, pp. 37–38. Lyme Disease: A Comprehen...

What treatment in practice looks like when patients fall outside the guideline

Within the ILADS-adjacent clinical community, treatment patterns diverge sharply from the 2020 IDSA recommendation. For the specific treatments that sit beyond or outside what the official guidelines recommend — and the evidence behind them — see Lyme experimental treatments evidence; this article stays on what the guidelines say and where they're clinically contested. The 2014 BMC review of the patient experience reports that "Treatment protocols can include regimens of multiple antibiotics (oral or parenteral), sometimes continuing for months or years" (BMC 2014). The same review notes substantial risk: "These protocols are associated with substantial risks such as out-of-pocket expenses, patient distress, potential harm, as well as increasing risk of selecting for antibiotic resistant bacteria." (BMC 2014) The 2022 HHS subcommittee report frames the off-guideline clinical reality sympathetically:

"As described above, PLD/CLD is a research-disadvantaged disease, similar to rare diseases, with few incentives driving treatment research. Treatment for PLD/CLD typically consists of generic off-label antibiotics. Clinical innovation and off-label treatments are often seen in diseases (for example, cancer) for which clinical needs exceed the available evidence base. Given the heterogeneity of the PLD/CLD population and its response to treatment, individualized care is customary. Hence, no single uniform course of treatment for this population is recognized as desirable, and the need for clinical innovation to address the needs of patients with PLD/CLD is strong. However, successfully innovative clinicians treating PLD/CLD have found themselves sanctioned for being ahead of their colleagues. The same logic applies to the use of CPGs. Guidelines adopted/endorsed for the treatment of patients with PLD/CLD should include the expertise of the clinicians who actually provide this care." — HHS, 2022. Access to Care and Educat...

Other voices point the other direction. The 2021 Nesgos review warns that "Current literature has highlighted the consequences of this confusion and misinformation in the overdiagnosis of CLD and use of unconventional, and at times dangerous, treatment approaches for this condition" (TTBD 2021), and observes that of 30 internet-recommended alternative therapies reviewed, "none are backed by evidence meeting the standards by which the scientific community accepts or rejects new treatments, and some are potentially harmful" (TTBD 2021). The review labels the core disagreement directly: "Diagnosis and treatment of LD has become a controversial topic in the US." (TTBD 2021)

Both descriptions can be accurate at the same time.

The access-to-care consequences

Whatever the science, the guideline split has downstream costs. For the patient-navigation angle — how patients get caught in the middle of the IDSA vs. ILADS split when seeking care — see IDSA vs. ILADS Lyme guidelines controversy; this article stays on what the guidelines say and where they're clinically contested, not on how patients navigate the fractured system. Insurance coverage tracks the IDSA recommendation. A patient witness in the 2012 Senate hearing:

"I am sure you know that much of the medical profession still does not believe in Chronic Lyme. It is because of this that insurance companies can decline benefits for most Lyme treatment except for early stages which requires 2 weeks of inexpensive antibiotics." — Senate, 2012, pp. 12–13. Lyme Disease: A Comprehen...

Clinicians practicing outside the IDSA regimen report professional exposure. From the same record:

"Doctors and medical professionals that follow the ILADS guidelines and properly treat Lyme disease do not accept health insurance, most of them for fear of losing their medical licenses for ‘‘over prescribing’’ antibiotics. So people like me who have no money to pay out-of-pocket are left to die a slow and miserable death." — Senate, 2012, pp. 62–63. Lyme Disease: A Comprehen...

The 2018 HHS report acknowledged the cost to patients of the unresolved dispute: "The lack of a clear path for treatment of persistent symptoms in some patients with Lyme disease and other tick-borne diseases not only amplifies patient suffering but also significantly increases health care costs." (HHS 2018)

The 2023 MDPI patient survey frames the clinical consequence bluntly:

"The contestation of CLD has created a climate in which doctors may be less inclined to believe that Lyme disease patients’ persistent symptoms are attributable to an ongoing infection. Thus, such patients may not receive treatments for their underlying infection." — MDPI, 2023. Medical Gaslighting and L...

And the 2021 Nesgos review documents the behavioral pattern that follows: "Patients in this group reported feelings of frustration or invalidation from HCPs perceived as paternalistic and often opted to leave mainstream medicine for alternative, or ‘Lyme literate’, providers" (TTBD 2021).

The federal position: both camps, uncertainty

The 2022 HHS Tick-Borne Disease Working Group landed on a recommendation that does not pick a side. Its finding was a language directive for federal websites:

"Finding 1.2. Fund and support modification of the Federal government websites, starting with the CDC and NIH websites, as well as educational materials and seminars for clinicians, the public, and public health departments to incorporate the following language: “the state of the science relating to persistent symptoms associated with Lyme disease, is limited, emerging, and unsettled; and increase public awareness that there are divergent views on diagnosis and treatment. Clinicians should consider that shared medical decision-making may be appropriate in some circumstances.”" — HHS, 2022. Access to Care and Educat...

The same report framed the decision-making implication: in the subcommittee's words, quoting Dr. Richard Schwartzstein, "“High value care is largely making the care consistent with the values of the patient”" (HHS 2022). And on standard of care itself, the subcommittee was willing to make the uncomfortable point that "Standard of care for Lyme disease can be difficult to define." (HHS 2022)

The federal framing, in short, is that the underlying medical disagreement is real, not a misunderstanding to be dispelled. A 2012 Senate witness had put it years earlier: "Schism and polarization within the medical community, heated by patient activism, resulted in ignoring the problem, preventing our strong and capable medical and scientific communities from finding the long overdue answers." (Senate 2012) The 2022 HHS review is what government looks like acknowledging, a decade later, that the schism has not closed on its own.

Sources

    Not medical advice. See a healthcare provider for medical decisions. Medical Disclaimer